First report of linezolid dependence in methicillin-resistant Staphylococcus aureus  by López-Hernández, I. et al.
RESEARCH NOTE BACTERIOLOGYFirst report of linezolid dependence in
methicillin-resistant Staphylococcus aureusI. López-Hernández1, M. Delgado Valverde1,
N. Batista Díaz1 and A. Pascual1,2
1) Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospitales
Universitarios Virgen Macarena y Virgen del Rocío and 2) Departamento de
Microbiología, Universidad de Sevilla, Sevilla, SpainAbstractLinezolid is used to treat infections caused by methicillin-resistant
Staphylococcus aureus (MRSA). We describe the ﬁrst report of
linezolid dependence in MRSA. The strain was isolated from a
respiratory sample of a cystic ﬁbrosis patient, and it showed a
thymidine-dependent small-colony variant phenotype. The effect
was not related to any known mechanisms implicated in S. aureus
resistance to linezolid. The clinical signiﬁcance of this
phenomenon needs further investigation.
Clinical Microbiology and Infection © 2015 European Society of
Clinical Microbiology and Infectious Diseases. Published by
Elsevier Ltd. All rights reserved.
Keywords: Cystic ﬁbrosis, dependence, linezolid, MRSA, small-
colony variant
Original Submission: 10 December 2014; Revised Submis-
sion: 1 March 2015; Accepted: 9 March 2015
Editor: JM. Rolain
Article published online: 13 April 2015Clin
Cli
httCorresponding author: I. López-Hernández, Department of
Microbiology, School of Medicine, Av. Sánchez Pizjuán s/n, 41009
Seville, Spain
E-mail: inlopezh@us.esThe presence of resistant isolates or the small-colony variants
of Staphylococcus aureus (SCV-SAs) can complicate the man-
agement of chronic lung infections in cystic ﬁbrosis [1,2].
Methicillin-resistant S. aureus (MRSA) strains are increasingly
being isolated, and linezolid is a therapeutic option [3].
Linezolid inhibits the synthesis of proteins on the 50S ribo-
somal subunit (domain V of the 23S rRNA gene). TheMicrobiol Infect 2015; 21: 650.e1–650.e4
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
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ﬁbrosis, this ﬁgure increases to 11% [4]. Resistance to line-
zolid can be mediated chromosomally by mutations in the 23S
rRNA or in the ribosomal proteins. The transfer mechanism
is mediated by the plasmid-borne ribosomal methyltransferase
gene, cfr, whose protein product methylates the 23S rRNA
[4,5].
SCV-SAs constitute small, slow-growing subpopulations
of bacteria with an unusual morphotype and biochemical
properties associated with clinical persistence. The SCV-SA
phenotype is usually associated with auxotrophy for
thymidine, haemin, and/or menadione. The isolation and
identiﬁcation of SCV-SAs is difﬁcult, and their prevalence
is probably underestimated (1–30%) [6], although they are
most often recovered from cystic ﬁbrosis patients (4–10%)
[1,2,7].
To our knowledge, this is the ﬁrst report of S. aureus with
total dependence on linezolid. A respiratory sample from a
cystic ﬁbrosis patient was processed in the laboratory, and tiny
colonies were obtained on Columbia blood agar plates (CBAs)
(Oxoid, Spain). No S. aureus with a normal colony size was
detected. The patient had received numerous cycles of pro-
longed treatment with trimethoprim–sulphamethoxazole and
linezolid, because of the presence of MRSA in previous respi-
ratory samples (including SCV-SA). The strain was identiﬁed as
an SCV-SA (SA606) by Gram stain, catalase reaction, and
coagulase with a commercial latex test (Staphaurex Plus; Remel,
Lenexa, KS, USA). A rapid latex test was used to determine
resistance to methicillin (MRSA-Screen; Denka-Seiken, Tokyo,
Japan). Matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (Bruker Daltonics, Bremen, Germany)
identiﬁed the isolate as S. aureus.
SA606 showed a stable SCV-SA phenotype on CBAs after 30
passages. SA606 was thymidine-dependent when auxotrophy
was tested as previously described [7].
Antimicrobial susceptibility was assayed with disk diffusion
on Mueller–Hinton agar supplemented with 5% sheep blood
(MHBA) (Oxoid), because SA606 did not grow in Mueller–
Hinton agar (Oxoid). The plates were incubated aerobically at
35–37°C for 24–48 h. In MHBA, the strain only grew in the
proximity of the linezolid disk (30 μg), and showed an SCV-SA
phenotype and total dependence on the antibiotic. Dependence
was also observed when a 10-μg linezolid disk was used
(Fig. 1a). This phenotype had not been detected before in SCV-
SA obtained from this patient.
A broth microdilution method was performed, according to
CLSI guidelines, with brain–heart infusion broth (Difco, BD,
Franklin Lakes, NJ, USA) and 2.0 McFarland inoculum [7,9]. The
MIC values (mg/L) obtained were as follows: amikacin, >128;ious Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Linezolid dependence in a small-colony variant of methicillin-
resistant Staphylococcus aureus in Mueller–Hinton agar supplemented
with 5% sheep blood. (a) Growth around a 10-μg linezolid disk. (b)
Growth in a zone surrounding a linezolid Etest strip (range:
0.25–64 mg/L).
CMI López-Hernández et al. Linezolid dependence in MRSA 650.e2ciproﬂoxacin, 128; clindamycin, 0.12; daptomycin, 0.5; erythro-
mycin, 0.25; gentamicin, 1; linezolid, 8; oxacillin, 64; rifampin,
0.002; teicoplanin,0.12; tetracycline,0.06; tobramycin, >128;
trimethoprim–sulphamethoxazole, >32; and vancomycin, 0.25 [8].
The Etest assay for linezolid in MHBA showed that SA606
could grow in a range of concentrations between 0.25 mg/L and
64 mg/L (Fig. 1b). In brain–heart infusion agar and on CBAs, the
Etest showed enhanced growth on the edge of the ellipse, sup-
porting partial dependence on linezolid in these media (Fig. 2).
The known mechanisms implicated in linezolid resistance in
strains with normal colony size were studied. Mutations in the
V domain in each 23S rRNA copy and in the ribosomal proteins
L3, L4 and L22 were determined as previously described [9,10].
A PCR assay was used to detect the presence of a cfr gene [11].
No mutations were detected in any 23S rRNA copy or ribo-
somal protein after molecular study. The cfr plasmid was not
present in SA606.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InThe staphylococcal chromosomal cassette mec type and
polymorphic X, or short sequence repeat, region of the
staphylococcal protein A (spa) gene were determined as pre-
viously described [12]. A restriction-modiﬁcation test based on
the hsdS gene was used to assign isolates to clonal complexes.
SA606 belonged to clonal complex 5, its spa type was t067, and
it harboured staphylococcal chromosomal cassette mec type IV.
This methicillin-resistant phenotype was the most prevalent in
our area [12].
SCV-SAs have been associated with persistent infections, and
all laboratories must be able to detect these variants [2,7].
These strains are often resistant to antibiotics, and, in the case
that we present here, we can see an example of how these
strains can become important reservoirs of antimicrobial
resistance, not only in the community but also in the hospital
environment [13].
Dependence on antimicrobial agents for growth has been
reported in S. aureus [14]. Recently, partial linezolid depen-
dence was even described in highly linezolid-resistant clinical
isolates of Staphylococcus epidermidis with a normal-size colony
[15,16]. Those strains, unlike ours, possessed mutations in both
23S RNA and the L3 ribosomal protein, which are known to be
associated with resistance to linezolid.
Linezolid dependence in our strain was not associated with
the mechanisms previously described for linezolid-resistant
strains of S. aureus, a ﬁnding that conﬁrms the presence of
unknown factors affecting susceptibility to linezolid in S. aureus.
This fact could reﬂect the complexity and unpredictability of
the interaction between linezolid and ribosomal function, which
deserves further investigation [17].
In some reports, the dependence of S. aureus on other
antimicrobials, such as vancomycin, implied the induction of an
alternative metabolic pathway for cell wall synthesis [14].
Similarly, the SCV-SA phenotype (related to alterations in
metabolic pathways) and the dependence shown by SA606
were probably the result of a metabolic shift connecting the
two phenomena. It is likely that the dependence evolved after
repeated exposure to linezolid in an adverse medium that
made the activation of an alternative route possible, giving to
SA606 a survival advantage for growth in the presence of
linezolid. This ﬁnding provides new perspectives for further
investigation of the relationship between resistance and
metabolism in bacteria, and its implications for clinical
outcome.
It is crucial to actively search for this persistent phenotype
in all cystic ﬁbrosis patients. The presence of these SCV-SAs
implies an increased probability of antimicrobial resistance,
and, if they escape detection in the laboratory, they may
emerge as an overlooked reservoir of antimicrobial
resistance.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 650.e1–650.e4
FIG. 2. Enhanced growth in the presence of
linezolid (Etest strip) in a small-colony variant
of methicillin-resistant Staphylococcus aureus.
(a) Columbia blood agar. (b) Brain–heart
infusion agar.
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